Moderna Inc. has updated its financial outlook, projecting 2025 revenue of approximately $1.9 billion, which is $100 million above the midpoint of the range previously communicated during its third quarter 2025 earnings call. The company also reported an improvement in expected 2025 GAAP operating expenses, reducing them by $200 million to a range of $5.0 to $5.2 billion. Moderna’s year-end 2025 cash, cash equivalents, and investments are estimated at $8.1 billion, reflecting a $0.6 billion draw from its recently announced $1.5 billion term loan facility. Looking ahead, Moderna reiterates a target of up to 10% revenue growth in 2026 and expects to further reduce GAAP operating expenses to approximately $4.9 billion that year, with plans to decrease operating expenses to $4.2 to $4.6 billion in 2027 on the path to targeted cash breakeven in 2028.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1125969) on January 12, 2026, and is solely responsible for the information contained therein.
Comments